Evaluation of the diurnal variation in the pharmacokinetics of zileuton in healthy volunteers

Journal of Clinical Pharmacology

Volumn 37, Issue 5, 1997, Pages 388-394

  Awni, Walid M ^a   Locke, Charles ^a   Dube, Louise M ^a   Cavanaugh, John H ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ZILEUTON;

ADULT; AREA UNDER THE CURVE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HYDROXYLATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; TABLET;

EID: 0031000242     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04316.x     Document Type: Review

References (8)

1. Bell RL, Young PR, Albert D, Lanni C, Summers JB, Brooks DW, et al: The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. Int J Immunopharmacol 1992; 14: 505-510.
2. Rouzer CA, Samuelsson B: On the nature of the 5-lipoxygenase reaction in human leukocytes: enzyme purification and requirement for multiple stimulatory factors. Proc Natl Acad Sci U S A 1985;82:6040-6044.
3. Batt DG: 5-lipoxygenase inhibitors and their anti-inflammatory activities. Prog Med Chem 1992;29:1-63.
4. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, et al: The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993;119:1059-1066.
5. Awni WM, Braeckman RA, Granneman GR, Witt G, Dubé LM: Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600 mg in healthy volunteers. Clin Pharmacokinet 1995;29(suppl 2):22-33.
6. Wong SL, Awni WM, Cavanaugh JH, El-Shourbagy T, Locke C, Dubé LM: The pharmacokinetics of single oral doses of zileuton 200 to 800 mg, its enantiomers, and its metabolites, in normal healthy volunteers. Clin Pharmacokinet 1995;29(suppl 2):9-21.
7. Awni WM, Cavanaugh JH, Witt G, Granneman GR, Dube LM: The effect of food on the pharmacokinetics of zileuton. Clin Pharmacokinet 1995;29(suppl 2):62-66.
8. Granneman GR, Braeckman RA, Erdman KA: Determination of a new 5-lipoxygenase inhibitor, zileuton, and its inactive N-dehydroxylated metabolite in plasma by high performance liquid chromatography. Clin Pharmacokinet 1995;29(suppl 2):1-8.